New Blood Test Detects Thousands of Fetal Genetic
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NIFS test identifies thousands of serious fetal genetic conditions—including Noonan, Charge, Stickler syndromes and cystic fibrosis—from a maternal blood sample, covering the 2,500-gene Genomics England foetal anomalies panel
- Dr Christopher Whelan of the Broad Institute is presenting the research at the European Society for Human Genetics conference in Gothenburg
- 565 pregnancies were tested at an average of 17 weeks of gestation, with NIFS identifying genetic variants across nearly 23,000 genes per fetus
- NIFS matched 95–99% of genetic variants found by amniocentesis and CVS, and more than 97% of clinically relevant variants in validation
- Amniocentesis carries a miscarriage risk of about 1 in 200 pregnancies, a factor Whelan says drives many women to decline invasive testing despite its diagnostic power
- Prof Alexandre Reymond of the University of Lausanne called the work a "tour de force" that will change reproductive medicine forever
- Prof Angus Clarke of Cardiff University warned that using the test for exploratory screening could surface genes of unknown significance, placing parents in a "really difficult position" and risking unnecessary medicalisation of healthy babies
Why it matters: For pregnancies where a fetal anomaly is suspected, NIFS matched 95–99% of amniocentesis's diagnostic yield in a 565-pregnancy validation—offering a safer alternative to a procedure that causes miscarriage in roughly 1 in 200 cases. The shift would expand prenatal screening from a handful of conditions like Down's syndrome to comprehensive coverage across nearly 23,000 genes, though Cardiff's Clarke cautioned that incidental findings could generate anxiety and over-medicalisation.
